Last reviewed · How we verify

biologic DMARDs — Competitive Intelligence Brief

biologic DMARDs (biologic DMARDs) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Biologic DMARD (disease-modifying antirheumatic drug). Area: Immunology / Rheumatology.

marketed Biologic DMARD (disease-modifying antirheumatic drug) Immunology / Rheumatology Small molecule Live · refreshed every 30 min

Target snapshot

biologic DMARDs (biologic DMARDs) — Kasr El Aini Hospital. Biologic DMARDs are immunosuppressive agents that target specific immune pathways to reduce inflammation and slow disease progression in autoimmune conditions.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
biologic DMARDs TARGET biologic DMARDs Kasr El Aini Hospital marketed Biologic DMARD (disease-modifying antirheumatic drug)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Biologic DMARD (disease-modifying antirheumatic drug) class)

  1. Kasr El Aini Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). biologic DMARDs — Competitive Intelligence Brief. https://druglandscape.com/ci/biologic-dmards. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: